Astellas, Daiichi Sankyo Outpacing Takeda In Return To Profit Growth
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma and Daiichi Sankyo say they are overcoming their recent losses of patent protection for key drugs and expect pipeline replacements to increase sales this fiscal year.